Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives

Area of Science:

• Oncology
• Immunotherapy

Background:

• Epithelial ovarian cancer (EOC) is a leading cause of gynecological cancer mortality.
• Current treatments offer limited improvement in patient prognosis, necessitating novel therapeutic approaches.

Purpose of the Study:

• To critically review early-phase clinical trial results of immune checkpoint inhibitors (CPIs) in epithelial ovarian cancer (EOC).
• To discuss the safety and activity of CPIs in EOC and identify reasons for suboptimal outcomes.
• To explore emerging therapeutic strategies aimed at enhancing patient survival in EOC.

Main Methods:

• Systematic review of early-phase clinical trials involving CPIs in EOC.
• Analysis of safety and efficacy data from published and presented trial results.
• Literature review to identify potential mechanisms of resistance and novel therapeutic combinations.

Main Results:

• CPIs have demonstrated limited overall efficacy and unsatisfactory results in initial EOC trials.
• Safety profiles of CPIs in EOC are generally manageable, but specific toxicities require attention.
• Significant heterogeneity in patient responses suggests the need for patient stratification and combination therapies.

Conclusions:

• Current CPI strategies show limited success in EOC, highlighting a critical unmet need for improved treatments.
• Understanding the reasons for CPI resistance is crucial for developing more effective therapeutic approaches.
• Future research should focus on novel combinations, biomarkers, and personalized treatment strategies to improve outcomes for EOC patients.